Lake Street Maintains Buy on Checkpoint Therapeutics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Thomas Flaten has maintained a 'Buy' rating on Checkpoint Therapeutics (NASDAQ:CKPT) but lowered the price target from $16 to $14.
August 16, 2023 | 5:08 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Checkpoint Therapeutics' price target has been lowered from $16 to $14 by Lake Street, though the 'Buy' rating is maintained.
The news of a lowered price target could potentially lead to a short-term decrease in stock price due to investor sentiment. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could balance out the initial negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100